CU20090114A7 - Formulación liposomal y proceso para la preparación del mismo - Google Patents

Formulación liposomal y proceso para la preparación del mismo

Info

Publication number
CU20090114A7
CU20090114A7 CU20090114A CU20090114A CU20090114A7 CU 20090114 A7 CU20090114 A7 CU 20090114A7 CU 20090114 A CU20090114 A CU 20090114A CU 20090114 A CU20090114 A CU 20090114A CU 20090114 A7 CU20090114 A7 CU 20090114A7
Authority
CU
Cuba
Prior art keywords
preparation
same
liposomal formulation
liposome
phase transition
Prior art date
Application number
CU20090114A
Other languages
English (en)
Other versions
CU23980B1 (es
Inventor
Lan Zhang
Li Zhang
Wenmin Guo
Dongmin Shen
Yanhui Li
Caixia Wang
Jinxu Wang
Chunlei Li
Original Assignee
Shijiazhuang Pharma Group Pharmaceutical Technology Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang Pharma Group Pharmaceutical Technology Shijiazhuang Co Ltd filed Critical Shijiazhuang Pharma Group Pharmaceutical Technology Shijiazhuang Co Ltd
Publication of CU20090114A7 publication Critical patent/CU20090114A7/es
Publication of CU23980B1 publication Critical patent/CU23980B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La presente invención se relaciona con una preparación farmacéutica liposómica que contiene un medicamento iónico multivalente, con un proceso para la elaboración de la preparación farmacéutica liposómica y con el uso de las mismas en el tratamiento de enfermedades, en donde el liposoma tiene un tamano aproximado de 30 a 80 nm y la bicapa fosfolipídica tiene un fosfolípido con una temperatura de transición de fase Tm mayor a la temperatura corporal, de manera tal que la temperatura de transición de fase del liposoma es mayor a la temperatura corporal.
CU2009000114A 2006-12-29 2009-06-29 Formulación liposomal y proceso para la preparación del mismo CU23980B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2006101023398A CN101209243B (zh) 2006-12-29 2006-12-29 一种脂质体药物及其制备方法
PCT/CN2007/071403 WO2008080367A1 (fr) 2006-12-29 2007-12-29 Composition de liposome et son procédé de préparation

Publications (2)

Publication Number Publication Date
CU20090114A7 true CU20090114A7 (es) 2011-02-24
CU23980B1 CU23980B1 (es) 2014-01-29

Family

ID=39588170

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2009000114A CU23980B1 (es) 2006-12-29 2009-06-29 Formulación liposomal y proceso para la preparación del mismo

Country Status (16)

Country Link
US (2) US20110002977A1 (es)
EP (1) EP2123260B1 (es)
JP (3) JP2010514708A (es)
KR (1) KR101126629B1 (es)
CN (1) CN101209243B (es)
AU (1) AU2007341803B2 (es)
BR (1) BRPI0720733A2 (es)
CA (1) CA2673924C (es)
CO (1) CO6190601A2 (es)
CU (1) CU23980B1 (es)
ES (1) ES2401526T3 (es)
HK (1) HK1133398A1 (es)
MX (1) MX2009007089A (es)
MY (1) MY150670A (es)
RU (1) RU2494729C2 (es)
WO (1) WO2008080367A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
US20090136937A1 (en) 2007-05-09 2009-05-28 Coleman Matthew A Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
US20110223675A1 (en) * 2008-11-20 2011-09-15 Terumo Kabushiki Kaisha Drug release means from liposomes and method for evaluating releasability
JP5622719B2 (ja) 2009-03-30 2014-11-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
DK2415470T3 (en) * 2009-03-30 2016-09-19 Eisai R&D Man Co Ltd liposome
AU2014200717B2 (en) * 2009-03-30 2016-02-25 Eisai R&D Management Co., Ltd. Liposome composition
CN101897667B (zh) * 2009-05-26 2012-01-25 石药集团中奇制药技术（石家庄）有限公司 一种盐酸多柔比星脂质体注射剂及其制备工艺
IN2012DN00570A (es) * 2009-07-14 2015-06-12 Polypid Ltd
CN102038640B (zh) * 2009-10-26 2013-11-13 石药集团中奇制药技术（石家庄）有限公司 一种含有胆固醇的peg修饰物的脂质体药物及其制备方法
WO2011143271A2 (en) * 2010-05-10 2011-11-17 Schmidt Michael A Therapeutic liposomes and methods for producing and using the same
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
US20150283272A1 (en) * 2010-10-27 2015-10-08 Vikas Kundra Dual mode gadolinium nanoparticle contrast agents
US20140328759A1 (en) * 2011-10-25 2014-11-06 The University Of British Columbia Limit size lipid nanoparticles and related methods
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
TR201908531T4 (tr) * 2012-11-20 2019-08-21 Arbutus Biopharma Corp Terapöti̇k kullanim i̇çi̇n li̇pozom kapsüllü vi̇nkri̇sti̇ni̇n preparasyonuna yöneli̇k geli̇şti̇ri̇lmi̇ş yöntem
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CA2906732C (en) 2013-03-15 2023-08-08 The University Of British Columbia Lipid nanoparticles for transfection and related methods
US10220095B2 (en) 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
KR101503492B1 (ko) * 2013-07-03 2015-03-19 전북대학교산학협력단 지질 및 리소좀 효소를 포함하는 리포좀 캡슐 및 그 제조방법
WO2015166985A1 (ja) * 2014-04-30 2015-11-05 富士フイルム株式会社 リポソーム組成物及びその製造方法
WO2015166986A1 (ja) * 2014-04-30 2015-11-05 富士フイルム株式会社 リポソーム組成物及びその製造方法
WO2017044899A1 (en) 2015-09-11 2017-03-16 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
CN111632030B (zh) 2015-11-02 2023-01-17 富士胶片株式会社 包含吉西他滨或其盐的脂质体组合物的制造方法
IL268099B1 (en) * 2017-01-18 2024-01-01 Temasek Life Sciences Laboratory Ltd Hyperstabilized liposomes that increase targeting of mitotic cells
WO2018204421A2 (en) 2017-05-02 2018-11-08 Lawrence Livermore National Security, Llc Momp telonanoparticles, and related compositions, methods and systems
WO2018204495A1 (en) * 2017-05-02 2018-11-08 Synthetic Genomics, Inc. Nanolipoprotein particles and related compositions methods and systems for loading rna
US11433143B2 (en) * 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
RU2728976C2 (ru) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Липосомный состав и его получение
CN108721644B (zh) * 2018-06-05 2021-06-08 常州金远药业制造有限公司 一种紫杉烷类药物脂质体制备方法
CN110711178A (zh) 2018-07-11 2020-01-21 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CA3167470A1 (en) * 2020-02-10 2021-08-19 Chunlei Li Use of mitoxantrone hydrochloride liposome for treating breast cancer
WO2021180184A1 (zh) * 2020-03-12 2021-09-16 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
WO2021208842A1 (zh) * 2020-04-13 2021-10-21 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
CN113876711A (zh) * 2020-07-01 2022-01-04 江苏长泰药业有限公司 一种盐酸阿霉素脂质体的制备工艺
JP2023537049A (ja) 2020-08-07 2023-08-30 石薬集団中奇制薬技術（石家庄）有限公司 ミトキサントロン塩酸塩リポソームとペグアスパラガーゼの使用
US20240024257A1 (en) * 2020-08-27 2024-01-25 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Use of mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone
AU2021399438A1 (en) * 2020-12-15 2023-07-06 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Use of mitoxantrone hydrochloride liposome
US20240122875A1 (en) 2021-04-16 2024-04-18 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Use of mitoxantrone hydrochloride liposome
CN115400083A (zh) 2021-05-28 2022-11-29 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体用于制备治疗晚期实体瘤的药物的用途
CN115770288A (zh) * 2021-09-07 2023-03-10 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体、硼替佐米和地塞米松治疗多发性骨髓瘤的用途
CN117940164A (zh) * 2022-04-26 2024-04-26 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5169635A (en) * 1989-11-17 1992-12-08 Fuji Photo Film Co., Ltd. Photoresponsive liposome
ZA952481B (en) * 1994-03-28 1995-12-15 Daiichi Seiyaku Co Liposomes with enhanced encapsulation capacity
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP0825852B1 (en) * 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
EP1037610A4 (en) * 1997-09-16 2004-07-07 Osi Pharm Inc COMPOSITIONS BASED ON LIPOSOMES COMPRISING CAMPTOTHECIN
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
BR9914601A (pt) * 1998-09-16 2001-10-23 Alza Corp Inibidor de topoisomerase capturado por lipossoma
DE60014093T2 (de) * 1999-07-16 2005-02-03 Alza Corp., Mountain View Liposomzusammensetzung mit Schutz vor Gefrier-/Aufbau-Schaden
ES2186484B1 (es) 2000-10-10 2004-07-01 Lipotec, S.A. Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
MXPA03003401A (es) 2000-10-16 2004-06-30 Neopharm Inc Formulacion liposomica de mitoxantrona.
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
AU2003287526A1 (en) * 2002-11-06 2004-06-03 Protein-stabilized liposomal formulations of pharmaceutical agents
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
US7205299B2 (en) * 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect
US7288396B2 (en) * 2003-09-11 2007-10-30 Kosan Biosciences Incorporated Biosynthetic gene cluster for leptomycins
RU2258530C1 (ru) * 2004-04-27 2005-08-20 Генкин Дмитрий Дмитриевич Способ профилактики и коррекции изменений кожи
KR101223366B1 (ko) * 2004-05-03 2013-01-16 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US20060034906A1 (en) * 2004-05-21 2006-02-16 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
CN1242740C (zh) * 2004-08-05 2006-02-22 常州太平洋药物研究所有限公司 米托蒽醌或盐酸米托蒽醌脂质体注射剂及其制备工艺
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006298844A (ja) * 2005-04-21 2006-11-02 Konica Minolta Medical & Graphic Inc リポソーム内に医薬化合物を内包するリポソーム含有製剤
AU2006241149A1 (en) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
WO2007028154A2 (en) * 2005-09-02 2007-03-08 Northwestern University Encapsulated arsenic drugs
EP3067046B1 (en) * 2005-12-08 2020-03-25 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US7703945B2 (en) 2006-06-27 2010-04-27 Cree, Inc. Efficient emitting LED package and method for efficiently emitting light
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
DK2415470T3 (en) * 2009-03-30 2016-09-19 Eisai R&D Man Co Ltd liposome
JP5480867B2 (ja) * 2011-10-07 2014-04-23 住友ゴム工業株式会社 空気入りタイヤ

Also Published As

Publication number Publication date
AU2007341803A2 (en) 2009-09-03
AU2007341803B2 (en) 2011-08-11
JP6187961B2 (ja) 2017-08-30
WO2008080367A1 (fr) 2008-07-10
MY150670A (en) 2014-02-28
CA2673924C (en) 2013-10-01
US20160235671A1 (en) 2016-08-18
KR20090094043A (ko) 2009-09-02
EP2123260A4 (en) 2010-03-17
EP2123260B1 (en) 2013-02-20
CU23980B1 (es) 2014-01-29
ES2401526T3 (es) 2013-04-22
RU2494729C2 (ru) 2013-10-10
AU2007341803A1 (en) 2008-07-10
JP2015180652A (ja) 2015-10-15
JP2010514708A (ja) 2010-05-06
CN101209243A (zh) 2008-07-02
MX2009007089A (es) 2009-10-08
US20110002977A1 (en) 2011-01-06
EP2123260A1 (en) 2009-11-25
CA2673924A1 (en) 2008-07-10
JP2013177397A (ja) 2013-09-09
HK1133398A1 (en) 2010-03-26
US10028913B2 (en) 2018-07-24
RU2009126983A (ru) 2011-02-10
CN101209243B (zh) 2010-12-08
CO6190601A2 (es) 2010-08-19
KR101126629B1 (ko) 2012-03-26
BRPI0720733A2 (pt) 2014-01-07

Similar Documents

Publication Publication Date Title
CU20090114A7 (es) Formulación liposomal y proceso para la preparación del mismo
CL2017000829A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino.
BRPI0608297A2 (pt) composições de lipossomos
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
CO6430467A2 (es) Péptidos útiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosméticas o farmacéuticas
AR077764A1 (es) Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos
EA200901112A1 (ru) Жидкие композиции, образующие дермальные пленки, для введения лекарственных препаратов в кожу
CR20120605A (es) Formulación tópica para un inhibidor de jak
ECSP13013010A (es) Preparación de gadobutrol de alta pureza
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
BRPI0510778A (pt) composição farmacêutica, processo para a preparação da mesma, método para o tratamento de rinite, e, uso de uma composição
CL2012000319A1 (es) Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
ES2542042R1 (es) Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
BR112012003283A2 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
AR087177A1 (es) Formulacion de una capsula que comprende montelukast y levocetirizina
PE20090910A1 (es) Composicion topica
CL2015000418A1 (es) Formulacion acuosa topica que comprende un farmaco antiangiogenico que es un anticuerpo anti-vegf y un liposoma formado de un lipido a base de peg; su uso en el tratamiento de una enfermedad o condicion relacionada con vegf; y metodo para tratar cancer, psoriasis y edema macular diabetico, entre otras enfermedades.
Alfaro‐Castellón et al. Dermoscopy distinction of eruptive vellus hair cysts with molluscum contagiosum and acne lesions
ES2879383T3 (es) Fórmulas mixtas
AR080970A1 (es) Uso de una composicion que contiene fosfolipidos para eliminar acumulaciones por lipolisis subcutanea
AR040599A1 (es) Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad
CY1121145T1 (el) Συστημα χορηγησης φαρμακων για χορηγηση μιας υδατοδιαλυτης, κατιοντικης και αμφιφιλης φαρμακευτικως ενεργης ουσιας
PE20120956A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
CL2016000543A1 (es) Uso de pidotimod o sus estereoisómeros y/o sales fisiológicamente aceptables para preparar un medicamento útil en el tratamiento de enfermedades asociadas con la inflamación, donde hay una hiperactivación aberrante de la vía no canónica de nfkb.

Legal Events

Date Code Title Description
FG Grant of patent